Akari Therapeutics (AKTX) Return on Capital Employed (2015 - 2026)
Akari Therapeutics (AKTX) posted Return on Capital Employed of 107.4% for Q1 2026, down 113.14% sequentially from 50.39% in Q4 2025, and up 31429.0% YoY from N/an in Q1 2025.
Akari Therapeutics (AKTX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 5 years of Return on Capital Employed data on file, last reported at 107.4% in Q1 2026.
- Quarterly Return on Capital Employed rose 31429.0% year-over-year to 107.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 107.4% (up 31429.0% YoY) and the FY2025 annual result came in at 46.85%, up 23987.0% from the prior year.
- Return on Capital Employed fell to 107.4% in Q1 2026 per AKTX's latest filing, from 50.39% in the prior quarter.
- The five-year high for Return on Capital Employed was 659.1% in Q1 2024, with the low at 1904.88% in Q4 2024.
- Average Return on Capital Employed over 3 years is 194.45%, with a median of 107.4% recorded in 2026.
- The widest YoY moves for Return on Capital Employed: up 185449 bps in 2025, down 108078 bps in 2025.
- Akari Therapeutics' Return on Capital Employed stood at 1904.88% in 2024, then jumped by 97 bps to 50.39% in 2025, then slumped by 113 bps to 107.4% in 2026.
- Business Quant data shows AKTX's Return on Capital Employed at 107.4% in Q1 2026, 50.39% in Q4 2025, and 386.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 10.37% |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -107.40% |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 10.46% |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 21.10% |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | 2.85% |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 10.19% |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | - |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 20.34% |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -21.94% |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn | -35.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.40% |
| Dec 31, 2025 | -50.39% |
| Sep 30, 2025 | -386.90% |
| Jun 30, 2025 | -359.67% |
| Mar 31, 2025 | -421.68% |
| Dec 31, 2024 | -1,904.88% |
| Sep 30, 2024 | 388.47% |
| Jun 30, 2024 | 433.26% |
| Mar 31, 2024 | 659.10% |
| Mar 31, 2016 | -66.01% |
| Dec 31, 2015 | -57.53% |
| Sep 30, 2015 | -842.18% |
| Jun 30, 2015 | -165.53% |
| Mar 31, 2015 | -180.18% |